New drug targets rare genetic cancers in early trial

NCT ID NCT03947385

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called IDE196 in people with certain cancers that have specific genetic mutations (GNAQ/11 or PRKC fusions). The cancers include metastatic uveal melanoma, cutaneous melanoma, and colorectal cancer. The trial has two phases: first to find safe doses, then to see if the drug shrinks tumors. About 336 adults will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Cancer Hematology Centers Western Michigan

    ACTIVE_NOT_RECRUITING

    Grand Rapids, Michigan, 49503, United States

  • Columbia University Medical Center - Herbert Irving Pavilion

    ACTIVE_NOT_RECRUITING

    New York, New York, 10032, United States

  • Duke University Medical Center

    RECRUITING

    Durham, North Carolina, 27710, United States

  • Princess Margaret Cancer Centre

    ACTIVE_NOT_RECRUITING

    Toronto, Ontario, OPG 7-815, Canada

  • Queensland

    ACTIVE_NOT_RECRUITING

    Woolloongabba, 4102, Australia

  • SCRI - Denver

    RECRUITING

    Denver, Colorado, 80218, United States

  • San Francisco Oncology Associates

    ACTIVE_NOT_RECRUITING

    San Francisco, California, 94115, United States

  • Sidney Kimmel Cancer Center at Thomas Jefferson University

    RECRUITING

    Philadelphia, Pennsylvania, 19107, United States

  • The Cleveland Clinic Foundation

    ACTIVE_NOT_RECRUITING

    Cleveland, Ohio, 44195, United States

  • The Sarah Cannon Research Institute/Tennessee Oncology

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • The University of Texas MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

  • UCLA Medical Center

    RECRUITING

    Los Angeles, California, 90095, United States

  • University of Cincinnati Cancer Center

    RECRUITING

    Cincinnati, Ohio, 45267, United States

  • University of Iowa

    ACTIVE_NOT_RECRUITING

    Iowa City, Iowa, 52242, United States

  • Westmead Hospital

    ACTIVE_NOT_RECRUITING

    Sydney, New South Wales, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.